OncLive TV

Ghayas C. Issa, MD, discusses the efficacy of revumenib in relapsed or refractory KMT2A-rearranged leukemias.

Albert Grinshpun, MD, MSc, discusses the utility of ctDNA as a predictive biomarker of endocrine therapy sensitivity in patients with HR+ breast cancer.

Erica L. Mayer, MD, MPH, discusses findings with neoadjuvant niraparib plus dostarlimab in ER-positive, HER2-negative, BRCA/PALB2-mutated breast cancer.

Mariya Rozenblit, MD, discusses how genomic alterations and TMB influence the efficacy of immune checkpoint inhibitors in HR+ metastatic breast cancer.

Maxwell Lloyd, MD, discusses a real-world study of elacestrant outcomes based on prior treatment and ESR1 mutation status in HR+ breast cancer.

Tracy I. George, MD, discusses and how ultra-sensitive duplex sequencing may address key limitations of current diagnostic tools for indolent systemic mastocytosis.

Elias Jabbour, MD, discusses frontline treatment considerations in newly diagnosed acute lymphocytic leukemia.

Bently P. Doonan, MD, discusses treatment strategies for patients with advanced melanoma who have progressed on checkpoint inhibitors.

Eytan M. Stein, MD, discusses efficacy findings from the phase 1/2 AUGMENT-101 study of revumenib in KMT2A-rearranged relapsed/refractory acute leukemia.

Azka Ali, MD, discusses findings from the S0221 trial of alternative adjuvant anthracycline and taxane dosing schedules in high-risk, early breast cancer.

Hope S. Rugo, MD, FASCO, discusses updated safety findings from the ELEVATE trial of elacestrant-based combinations in ER+/HER2– metastatic breast cancer.

Virginia Kaklamani, MD, DSc, discusses an analysis of ESR1 allelic frequencies in elacestrant-exposed ER+/HER2– metastatic ESR1-mutated breast cancer.

Aditya Bardia, MD, MPH, FASCO, discusses the efficacy of T-DXd in HER2-low/ultralow metastatic breast cancer by disease progression on prior therapy.

John M. Burke, MD, discusses results from a US community-based healthcare practitioner survey on challenges in initiating venetoclax for patients with CLL.

Eunice S. Wang, MD, on ziftomenib plus intensive induction in newly diagnosed, NPM1-mutated or KMT2A-rearranged acute myeloid leukemia.

Rachel E. Rau, MD, discusses findings that show blinatumomab plus chemotherapy improves DFS in newly diagnosed B-ALL.

Wade T. Iams, MD, discusses the importance of performing anti-VGCC antibody testing for suspected Lambert-Eaton Myasthenic Syndrome in SCLC.

Andrew Kuykendall, MD, discusses the advantages of treatment with momelotinib vs older-generation JAK inhibitors in myelofibrosis.

Timothy S. Fenske, MD, MS, shares outcomes from the phase 3 ECOG-ACRIN EA4151 trial of patients with mantle cell lymphoma after first MRD-negative CR.

Dasom (Caroline) Lee, MD, discusses real-world early outcomes of treatment with second-line axi-cel in relapsed/refractory large B-cell lymphoma.

Christina Poh, MD, discusses results from the phase 3 inMIND study of tafasitamab plus lenalidomide and rituximab for relapsed/refractory follicular lymphoma.

Matthew Matasar, MD, discusses treatment with odronextamab monotherapy in patients with diffuse large B-cell lymphoma following CAR T-cell therapy.

C. Ola Landgren, MD, PhD, discusses tocilizumab prophylaxis in relapsed/refractory myeloma treated with teclistamab, elranatamab, or talquetamab.

Mikkael A. Sekeres, MD, discusses the results of combining luspatercept and lenalidomide in lower-risk, non–5q deletion myelodysplastic syndromes.

Robert M. Rifkin, MD, FACP, discusses the safety and efficacy of the phase 3 Dreamm-7 trial in patients with relapsed/refractory multiple myeloma.

David Samuel Dicapua Siegel, MD, discusses preliminary findings from the phase 1/2 CA057-003 trial of mezigdomide in relapsed/refractory multiple myeloma.

Laahn Foster, MD, shares data on daratumumab and lenalidomide vs lenalidomide alone as maintenance in newly diagnosed multiple myeloma after transplant.

Christine Mauz-Koerholz, MD, PhD, discusses updated results from the phase 2 KEYNOTE-667 trial, which were shared at the 2024 ASH Annual Meeting.

Marcella Ali Kaddoura, MD, discusses genomic determinants of clinical outcomes in myeloma with t(11;14)(CCND1;IGH) treated with venetoclax.

Ira Zackon, MD, discusses findings on the real-world utilization of bispecific antibodies in the treatment of relapsed/refractory multiple myeloma in the community oncology setting.